Research progress and applications of epigenetic biomarkers in cancer

Jianjun Gao; Wujiang Shi; Jiangang Wang; Canghai Guan; Qingfu Dong; Jialin Sheng; Xinlei Zou; Zhaoqiang Xu; Yifei Ge; Chengru Yang; Jiehan Li; Haolin Bao; Xiangyu Zhong; Yunfu Cui

doi:10.3389/fphar.2024.1308309

Frontiers in Pharmacology (Apr 2024)

Research progress and applications of epigenetic biomarkers in cancer

Jianjun Gao,
Wujiang Shi,
Jiangang Wang,
Canghai Guan,
Qingfu Dong,
Jialin Sheng,
Xinlei Zou,
Zhaoqiang Xu,
Yifei Ge,
Chengru Yang,
Jiehan Li,
Haolin Bao,
Xiangyu Zhong,
Yunfu Cui

Affiliations

Jianjun Gao: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Wujiang Shi: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Jiangang Wang: Department of General Surgery, Tangdu Hospital, Air Force Medical University, Xi’an, China
Canghai Guan: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Qingfu Dong: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Jialin Sheng: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Xinlei Zou: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Zhaoqiang Xu: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Yifei Ge: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Chengru Yang: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Jiehan Li: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Haolin Bao: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Xiangyu Zhong: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China
Yunfu Cui: Department of Hepatopancreatobiliary Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China

DOI: https://doi.org/10.3389/fphar.2024.1308309
Journal volume & issue: Vol. 15

Abstract

Read online

Epigenetic changes are heritable changes in gene expression without changes in the nucleotide sequence of genes. Epigenetic changes play an important role in the development of cancer and in the process of malignancy metastasis. Previous studies have shown that abnormal epigenetic changes can be used as biomarkers for disease status and disease prediction. The reversibility and controllability of epigenetic modification changes also provide new strategies for early disease prevention and treatment. In addition, corresponding drug development has also reached the clinical stage. In this paper, we will discuss the recent progress and application status of tumor epigenetic biomarkers from three perspectives: DNA methylation, non-coding RNA, and histone modification, in order to provide new opportunities for additional tumor research and applications.

Published in Frontiers in Pharmacology

ISSN: 1663-9812 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Therapeutics. Pharmacology
Website: http://journal.frontiersin.org/journals/pharmacology

About the journal

Abstract

Keywords